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ABSTRACT 
Background: Racemic (R,R/S,S)-formoterol is a long-acting [3-agonist com- 
posed of a 50:50 mixture of (R,R)- and (S,S)-enantiomers. 
Objective: The aim of this study was to determine whether (R,R)-formoterol 
and (R,R/S,S)-formoterol have differing effects on airway contraction and relaxa- 
tion in vitro. 
Methods: Cylindrical airway segments 3-mm long were isolated from the 
mid-trachea of healthy Sprague-Dawley rats and placed in a modified Krebs- 
Henseleit solution. Dose-response curves of bethanechol-induced contraction 
(measured as milligrams of tension) and the concentration of bethanechol that 
elicited 50% to 75% of maximal contraction (EC50_75) were determined. The air- 
way cylinders were then precontracted with bethanechol at the EC50_75 and 
exposed to different concentrations of (R,R)-formoterol (0.0001-1.0 1JM) or 
(R,R/S,S)-formoterol (0.0002-2.0 1JM). Each concentration of the 2 formoterol 
formulations contained the same amount of (R,R)-enantiomer (eg, [R,R]- 
formoterol 0.0001 1JM and [R,R/S,S]-formoterol 0.0002 1JM contained the same 
amount of [R,R]-enantiomer). The relaxation percentage in response to for- 
moterol was calculated as a reduction in tension (in milligrams) in relation to 
baseline tension in the precontracted state, with each tracheal cylinder serving 
as its own control. To determine the effect of (R,R)-formoterol n airway con- 
traction, tracheal cylinders were incubated with (R,R)- or (R,R/S,S)-formoterol 
before electrical field stimulation (EFS). 
Results: Tracheae from 56 three-week-old Sprague-Dawley rats were used in 
the study. The relaxation percentage of precontracted trachea was significantly 
greater after exposure to (R,R)-formoterol than to (R,R/S,.C)-formoterol at a 
2-fold higher concentration (P = 0.03; general linear model with repeated mea- 
sures analysis comparing the 2 groups of animals). However, in a post hoc analy- 
sis, the mean (SE) relaxation percentage of precontracted trachea was signifi- 
cantly greater only after exposure to (R,R)-formoterol 0.01 1JM than to 
(R,R/S,S)-formoterol 0.02 1JM (15.6% [5.8%] vs 39.0% [5.6%]; P < 0.05, unpaired 
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t test). EFS-induced airway contraction was significantly less in tracheal cylin- 
ders incubated in (R,R)-formoterol compared with those incubated in (R,R/S,S)- 
formoterol at a 2-fold higher concentration (P = 0.05; general linear model with 
repeated measures analysis comparing the 2 groups of animals). However, in 
the post hoc analysis, mean (SE) EFS-induced tracheal contraction was signifi- 
cantly less only in (R,R)-formoterol 0.01 1JM compared with (R,R/S,S)-formoterol 
0.02 1JM at 10 V (1070 [55] mgvs 1225 [28] mg; P< 0.05, unpaired t test). 
Conclusion: We found that (R,R)-formoterol may induce greater elaxation 
of precontracted airway smooth muscle cells than (R,R/S,S)-formoterol and that 
(R,R)-formoterol may have a greater inhibitory effect on the endogenous cho- 
linergic and excitatory nonadrenergic, noncholinergic ontractile airway 
responses than (R,R/S,S)-formoterol. We speculate that the presence of the 
(S~S~)-enantiomer in (R,R/S,S)-formoterol may impair airway relaxation of pre- 
contracted trachea in rats. (Curr Ther Res Clin Exp. 2007;68:249-261) Copyright © 
2007 Excerpta Medica, Inc. 
Key words: (R,R)-formoterol, (R,R/S~)-formoterol, electrical field stimulation, 
airway contraction, airway relaxation. 
INTRODUCTION 
In moderate to severe asthma, levalbuterol ([R]-enantiomer of albuterol) 
has been found to provide a better therapeutic index than racemic albuterol, 
which is an equal mixture of (R)- and (S)-enantiomers. 1 In an in vitro study, (S)- 
salbutamol was found to significantly increase the contractile response of iso- 
lated human bronchi to histamine and leukotrienes. 2 (S)-Albuterol was also 
found to increase intracellular f ee calcium by activating muscarinic receptors 
in airway smooth muscles. 3 (S)-Enantiomers of albuterol and formoterol have 
also been implicated in the release of inflammatory mediators and the activa- 
tion of proinflammatory pathways in human airway smooth muscle cells. 4,5 
These results may explain some of the adverse vents associated with racemic 
forms of [3-agonists, which have equal mixtures of (R)- and (S)-enantiomers. 
Racemic (R,R/S,S)-formoterol is a long-acting [3-agonist composed of an equal 
mixture of (R,R)- and (S,S)-enantiomers. 
Few studies have examined whether the (S,S)-enantiomer component of the 
racemic mixture has any detrimental effects on airways in vitro. [3-Adrenergic 
receptors are extensively distributed in the large and small airways of rats. 6 In 
vitro isometric relaxation in response to [32-agonists has been reported in tra- 
cheae of Sprague-Dawley rats. 7,8 Our previous tudy 9and the report by Szarek 
et al 1° found that precontracted airways at 50% to 75% of the maximal response 
to bethanechol provided the optimal condition to study bronchodilatation in 
vitro in Sprague-Dawley rats. 
The aim of this study was to determine whether (R,R)-formoterol and 
(R,R/S,S)-formoterol have differing effects on airway contraction and relaxation 
in vitro. 
250 
M.J. Mhanna et aL 
MATERIALS AND METHODS 
The design and conduct of this study were approved by the institutional review 
board of the MetroHealth Medical Center, Case Western Reserve University, 
Cleveland, Ohio. 
Animal Preparation 
Healthy weanling Sprague-Dawley rats were used in the study. The tracheae 
of 1 group of rats were used to determine the concentration of bethanechol 
that elicited 50% to 75% of maximal contraction (EC50_75) of the trachea. 
Another group was used to determine the relaxation percentage with (R,R)- or 
(R,R/S,S)-formoterol of tracheae precontracted with bethanechol. To study the 
endogenous cholinergic and excitatory nonadrenergic, noncholinergic (NANC) 
contractile airway responses to electrical field stimulation (EFS), a third group 
was used to study EFS-induced tracheal contraction in the presence of 
(R,R)- or (R,R/S,S)-formoterol. The fourth group was used to study bethanechol- 
induced tracheal contraction in tracheae incubated with (R,R)- or (R,R/S,S)- 
formoterol. 
The rats were euthanized and the trachea of each was removed. Under the 
dissecting microscope, each trachea was freed of adventitia nd fat tissue, as 
described in previous studies. 9,1° One cylindrical airway segment 3 mm in 
length was isolated from the mid-trachea of each animal and placed in a modi- 
fied Krebs-Henseleit solution with the following composition (mM): sodium 
chloride, 118.2; sodium bicarbonate, 25; potassium chloride, 4.6; potassium 
phosphate, 1.2; magnesium sulfate, 1.2; calcium chloride, 2.5; and 10% dextrose; 
with the pH adjusted to 7.4. The solution was continuously aerated with 5% car- 
bon dioxide balanced with oxygen. 
The tracheal cylinders were then suspended between a sturdy glass rod and 
a force displacement transducer (FT03, Grass Instruments, Quincy, Massachu- 
setts) connected to an amplifier. Generated force was continuously monitored 
and recorded on a rectilinear chart recorder (LDS Test and Measurement, Mid- 
dleton, Wisconsin). The cylinders were allowed to equilibrate in the organ bath 
for 40 to 45 minutes before being challenged. The optimal ength at which maxi- 
mal isometric force developed was obtained for each cylinder by 0.1-g incre- 
ments of load until EFS (5-V alternating current applied through platinum elec- 
trodes, 250 mA/cm 2) applied for 10 seconds at 4-minute intervals gave a 
reproducible maximal response. 9 A cumulative concentration-response curve 
to bethanechol and the resultant concentration of bethanechol that elicited 
EC50_75 were obtained. 9 
Relaxation Studies 
The tracheal cylinders were washed, equilibrated, and precontracted with 
bethanechol to their EC50_75, after which they were exposed to different concen- 
trations of (R,R)-formoterol (0.0001-1.0 1JM) or (R,R/S,S)-formoterol (0.0002- 
2.0 1JM). Each concentration of the 2 formoterol formulations contained the 
251 
CURRENT THERAPEUTIC RESEARCH 
same amount of (R,R)-enantiomer (eg, [R,R]-formoterol 0.0001 1JM and [R,R/S,S]- 
formoterol 0.0002 1JM contained the same amount of [R,R]-enantiomer). The 
relaxation percentage in response to formoterol was calculated from the reduc- 
tion in tension (in mg) in relation to baseline tension in the precontracted state, 
with each tracheal segment serving as its own control (before and after drug 
exposure). When airway cylinders were precontracted to EC50_75, baseline 
tension was observed to decrease over time. After the application of (R,R)- 
or (R,R/S,S)-formoterol, there was a relaxation of the airway cylinders followed 
by a recovery and a return to a new baseline tension that was lower than the 
original baseline tension. The new higher concentrat ion of the drug was not 
applied to the tracheal cylinders until the cylinders had reached the new base- 
line tension. 
Contraction Studies 
To study airway contract ion in response to EFS in the presence of (R,R)- or 
(R,R/S,S)-formoterol, tracheal cylinders from a separate group of rats were iso- 
lated, and a dose-response curve to EFS-induced tracheal contraction was ob- 
tained in the presence of (R,R)- or (R,R/S,S)-formoterol. Tracheal cylinders were 
incubated with (R,R)-formoterol 0.01 1JM and 1.0 1JM or (R,R/S,S)-formoterol 
0.02 1JM and 2.0 1JM for 20 minutes before exposure to EFS at different voltages. 
EFS was applied for 10 seconds to each trachea at 2, 4, 6, 8, and 10 V separated 
by 4-minute intervals. 
To study airway contract ion in response to bethanechol,  tracheae were 
removed from another group of rats, and a concentrat ion-response curve to 
bethanechol  was obtained in the presence of (R,R)- or (R,R/S~S~)-formoterol. 
Tracheal cylinders were incubated with (R,R)-formoterol 0.01 1JM or 1.0 1JM or 
with (R,R/S,S)-formoterol 0.02 1JM or 2.0 1JM for 20 minutes before exposure to 
different concentrat ions of bethanechol  (0.3-1000.0 1JM). 
Statistical Analysis 
Comparisons among the various experimental groups were made using a 
general linear model with repeated measures. The dependent variable was the 
relaxation percentage of precontracted tracheae over time. The independent 
variable was (R,R)-formoterol versus (R,R/S,S)-formoterol, with the repeated 
measure being increasing drug concentrations on the tracheal sections. A simi- 
lar analysis was used to assess both EFS-induced airway contraction and 
bethanecol-induced airway contraction of tracheae preincubated with (R,R)- or 
(R,R/S,S)-formoterol over time. The assumption of homogeneity of variances 
was met in all the analyses (Levine's test of equality-of-error variances). If the 
between-subject effects were statistically significant, post hoc, pooled-variance, 
unpaired t tests were used for each of the time periods (different drug concen- 
trations) to determine the differences between the 2 study drugs. P ~ 0.05 was 
considered statistically significant. Data were analyzed using SPSS version 14.0 
(SPSS Inc., Chicago, Illinois). All data are expressed as mean (SE). 
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RESULTS 
Fifty-six 3-week-old Sprague-Dawley rats were divided into the 4 study groups, 
as mentioned previously. 
The concentration-response curve to bethanechol was obtained (n = 8 rats). 
Bethanechol 10 pM was found to be the optimal concentration necessary to 
elicit EC50_75. Bethanechol-induced airway contraction increased from a mean 
(SE) tension of 40 (18) mg at 0.3 pM to 2594 (156) mg at 1000 pM (Figure 1). 
To determine the effect of (R,R)-formoterol on airway relaxation of pre- 
contracted trachea, tracheal cylinders (n = 16) incubated in bethanechol 
10 pM (EC50_75) were exposed to different concentrations of (R,R)-formoterol r 
(R,R/S,S)-formoterol. The relaxation percentage of precontracted trachea in 
response to (R,R)-formoterol was significantly greater than the relaxation per- 
centage in response to (R,R/S,S)-formoterol at equivalent concentrations (P = 
0.03, general inear model with repeated measures analysis comparing the 
2 groups of animals) (Figure 2). However, in a post hoc analysis, the mean (SE) 
relaxation percentage of precontracted trachea was significantly greater only 
after exposure to (R,R)-formoterol 0.01 pM than to (R,R/S,S)-formoterol 0.02 pM 
(15.6% [5.8%] vs 39.0% [5.6%]; P< 0.05, unpaired t test). The relaxation percent- 
age varied from 0% to 46.7% (4.2%) with (R,R)-formoterol 0.0001 pM and 1 pM, 
respectively, and from 0% to 33.8% (5.9%) with (R,R/S,S)-formoterol 0.0002 pM 
and 2 pM, respectively. In a post hoc analysis, there was only a statistically sig- 
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Tracheal concentration-response curve to bethanechol in Sprague-Dawley 
rats (0.3-1000 DM; n = 8). 
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Figure 2. The relaxation percentage of tracheae from Sprague-Dawley rats precon- 
tracted with bethanechol in response to (R,R)- and (R,R/S,S)-formoterol 
at concentrations ranging from 0.0001 to 1.0 IJM and 0.0002 to 2.0 IJM, 
respectively (n = 16, 8 animals in each group; P = 0.03, general linear 
model with repeated measures analysis comparing the 2 groups of animals). 
*P < 0.05, by unpaired t test. 
nificant difference between tracheae xposed to (R,R)-formoterol 0.01 tiM and 
(R,R/S,S)-formoterol 0.02 tiM (Figure 2) (39.0% [5.6%] vs 15.6% [5.8%]; P< 0.05, 
unpaired t test). 
To determine the effect of (R,R)-formoterol n airway contraction, tracheal 
cylinders (n = 16) were incubated with (R,R)- or (R,R/S,S)-formoterol before EFS. 
EFS-induced tracheal contraction was significantly lower in the presence of 
(R,R)-formoterol 0.01 tiM versus (R,R/S,~C)-formoterol 0.02 tiM (Figure 3A) (P = 
0.05, general inear model with repeated measures analysis comparing the 
2 groups of animals). EFS-induced tracheal contraction increased from 0 mg to 
1070 (55) mg at 0 V and 10 V, respectively, with (R,R)-formoterol 0.01 tiM (n = 8) 
and from 0 mg to 1225 (28) mg at 0 V and 10 V, respectively, with (R,R/S,S)- 
formoterol 0.02 tiM (n = 8) (Figure 3A). However, in a post hoc analysis, EFS- 
induced tracheal contraction was significantly less only in (R,R)-formoterol 
0.01 tiM compared with (R,R/S,S)-formoterol 0.02 tiM at 10 V (1070 [55] mg vs 
1225 [28] mg; P< 0.05, unpaired t test). No significant differences were seen with 
(R,R)-formoterol 1.0 tiM compared with (R,R/S,~C)-formoterol 2.0 tiM (n = 8) 
(Figure 3B). There was no significant difference in bethanechol-induced airway 
254 
M.J. Mhanna et al. 
A 
E 
v 
0 
",~ 
E 
v 
c- 
O °m 
0 
LJ 
r .  
1600 - 
1440 - 
1280 - 
1120 - 
960 - 
800 - 
640 - 
480 - 
320 - 
160 - 
0£  
0 
(R, R)- Form oterol 
(R,R/S,S)-Formoterol 
r I I I I 
2 4 6 8 10 
EFS (V)  
1600 - 
1440 - 
1280 - 
1120 - 
960 - 
800 - 
640 - 
480 - 
320 - 
160 - 
0~'  
0 
(R, R)- Form oterol 
(R,R/S,S)-Formoterol 
1 I I I I 
2 4 6 8 10 
EFS (V)  
F igure  3. E lect r ica l  f ie ld  s t imu la t ion  (EFS) - induced t rachea l  cont ract ion  in the  presence  
o f  (A)  (R,R)- o r  (R,R/S,5)-formoterol at  0.01 luM (n  = 8) and  0 .02  luM (n  = 8) ,  
respect ive ly  (P  = 0 .05 ;  genera l  l inear  mode l  w i th  repeated  measures  
ana lys i s  compar ing  the  2 groups  o f  an imals )  and  (B)  (R,R)- o r  (R,R/S,S)- 
fo rmotero l  a t  1.0 luM (n  = 8)  and  2 .0  luM (n  = 8) ,  respect ive ly .  *P < 0.05,  by  
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contraction i  the presence of (R,R)-formoterol r (R,R/S,S)-formoterol at 2 dif- 
ferent concentrations (n = 16) (Figure 4). 
DISCUSSION 
We found that the relaxation of bethanechol-precontracted trachea with (R,R)- 
formoterol was greater than that induced by equivalent concentrations of
(R,R/S,S)-formoterol in this animal model. We also found that that EFS-induced 
airway contraction was greater with (R,R/S,S)-formoterol than with (R,R)- 
formoterol in vitro, while no differences were found in bethanechol-induced 
contractions. Our findings suggest hat (S,S)-formoterol impairs the ability of 
(R,R)-formoterol to relax the airway and to protect against contraction induced 
by EFS but not by bethanechol in vitro. 
In a study in ovalbumin-sensitized and -nonsensitized guinea pigs, Handley et 
a111 used isolated strips of guinea pig tracheae that had been precontracted 
with histamine. The addition of (R,R)-formoterol produced greater dose-related 
airway relaxation than (R,R/S,S)-formoterol. These data are consistent with our 
findings. In our study using tracheal preparations from nonsensitized Sprague- 
Dawley rats, (R,R)-formoterol produced concentration-related airway relaxa- 
tion of precontracted tracheal cylinders that was greater than that seen with 
(R,R/S,S)-formoterol. However, Schmidt et a112 did not find a difference in relaxa- 
tion of human and guinea pig bronchi precontracted with carbachol or hista- 
mine when treated with (R,R)- or (R,R/S,S)-formoterol. Their results might have 
differed from ours because the airway cylinders they used were precontracted 
to a greater extent (EC90) and with different spasmogens (carbachol and hista- 
mine). The tracheal cylinders used in our study may have also behaved iffer- 
ently from the bronchiolar cylinders used in their study. 
EFS induces the release of acetylcholine and excitatory NANC substances 
from airway sensory nerves. 13,14 Verleden et a113 found that formoterol pro- 
duced concentration-dependent inhibition of the NANC contraction of guinea 
pig bronchi n vitro. To determine if (R,R)-formoterol inhibited the NANC con- 
traction induced by EFS more than (R,R/S,S)-formoterol, we incubated tracheal 
cylinders in (R,R)- or (R,R/S~S~)-formoterol pri r to EFS exposure at different 
voltages. (R,R)-Formoterol had a greater inhibitory effect on EFS-induced air- 
way contraction than (R,R/S,S)-formoterol. Our findings were consistent with 
previous studies that indicated that [32-agonists inhibit NANC neural bron- 
choconstrictor responses in vitro 13 and that [3-agonists inhibit cholinergic 
nerve-induced contractions. 15 However, we were the first to report that (R,R)- 
formoterol induced greater inhibition of EFS-induced airway contraction com- 
pared with (R,R/S,S)-formoterol. One potential explanation might be exagger- 
ated release of endogenous acetylcholine after EFS in the presence of the 
(S~S~)-enantiomer, as previously found by Zhang et al. 16 These authors reported 
that (S,S)-formoterol significantly increased acetylcholine release with EFS in 
equine tracheal smooth muscles. Increased intracellular calcium concentration 
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might be another potential mechanism responsible for the exaggerated airway 
contraction in the presence of the (S,S)-enantiomer. Mitra et al 3 reported that 
another ineffective but not inert isomer of albuterol, (S)-albuterol, increased 
intracellular calcium concentration, whereas the effective isomer, (R)-albuterol, 
decreased intracellular calcium concentration i  bovine tracheal smooth mus- 
cle cells. In our study, the difference in EFS-induced contraction between the 
(R,R)- and (R,R/S,S)-exposed tracheae might have been the result of increased 
intracellular calcium concentration i  the presence of the (S,S)-enantiomer in 
(R,R/S,S)-formoterol. 
The (S,S)-enantiomer of (R,R/S,S)-formoterol may be responsible for the 
exaggerated NANC contractile responses seen in our experimental model. Our 
findings are consistent with those of other investigators. Keir et a117 found that 
treating uinea pigs with racemic or (S)-albuterol increased airway responsive- 
ness to bradykinin and capsaicin, indicating the role of the sensory nerves in 
bronchial hyperresponsiveness seen with the chronic use of racemic albuterol. 
Mazzoni et a118 reported that IV infusion of (S)-salbutamol induced airway 
hyperresponsiveness to histamine in guinea pigs and that hyperresponsiveness 
was abolished by bilateral vagal nerve section. 
We did not find any difference in bethanechol-induced airway contraction 
between tracheal cylinders preincubated with (R,R)- or (R,R/S~S~)-formoterol. 
One explanation for our findings might be associated with the greater inhibitory 
effect of [3-agonists on EFS-induced contraction than on exogenous cholinergic- 
induced contraction. 15,19 Rhoden el a115 found that [3-agonists inhibit cholinergic 
nerve-induced contractions of human bronchi more potently than contractions 
induced by exogenous acetylcholine. Bergendal et a119 also found that (R,R/S,S)- 
formoterol produced a greater inhibitory effect in preparations contracted by 
EFS than in preparations contracted by exogenously added acetylcholine. It is 
possible that in our study the effect of (R,R)- versus (R,R/S~S~)-formoterol might 
not be detected because of the small changes in inhibition of airway contrac- 
tions induced by bethanecol (an exogenous cholinergic substance). 
Study Limitations 
The results of this study might have differed if it had been conducted in vivo. 
Some clinical studies have supported 2°-24 and others have not supported 25-28 
the use of [3-agonists without he (S,S)-enantiomers. In addition, we studied tra- 
cheal cylinders. Large airways might respond differently to [3-agonists and EFS 
than smaller airways and bronchi. The number of [32-receptors is higher in the 
smooth muscle of the small airways than the large airways in humans and rats, 29 
and [3-adrenergic responses are weaker in the large peripheral airways than in 
the small peripheral airways. 3° Our results might have differed if bronchial cylin- 
ders had been studied instead of tracheal cylinders. When airway cylinders are 
precontracted to 50% to 75% of their maximal contraction for a prolonged time, 
there will be a time-dependent loss of their baseline tension, a factor that might 
have affected the accuracy of our relaxation percentage findings. 
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In vivo studies are needed to val idate the significance of our in vitro findings. 
Future studies are needed to determine the clinical importance of the differ- 
ences seen in vitro of tracheal  relaxation and contract ion in response to (R,R)- 
and (R,R/S,S)-formoterol. 
CONCLUSION 
(R,R)-Formoterol may induce greater relaxation of precontracted airway 
smooth  muscle cells than (R,R/S,~C)-formoterol, and (R,R)-formoterol may have 
a greater inhibitory effect on the endogenous cholinergic and excitatory NANC 
contracti le airway responses than (R,R/S,S)-formoterol. 
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